Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr514.50 DKK
Change Today -3.00 / -0.58%
Volume 456.6K
GEN On Other Exchanges
As of 11:04 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

genmab a/s (GEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/16/15 - kr558.00
52 Week Low
05/20/14 - kr180.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENMAB A/S (GEN)

Related News

No related news articles were found.

genmab a/s (GEN) Related Businessweek News

No Related Businessweek News Found

genmab a/s (GEN) Details

Genmab A/S, a biotechnology company, develops human antibody therapeutics for the treatment of cancer in Denmark, the Netherlands, the United States, and internationally. The company markets Ofatumumab, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia. Its products under development include Ofatumumab that is in Phase III clinical studies to treat follicular lymphoma and pemphigus vulgaris; and Phase II clinical studies for the treatment of relapsing-remitting multiple sclerosis, as well as Daratumumab, a CD38 monoclonal antibody that is in Phase III clinical studies to treat multiple myeloma. The company’s products under development also comprises HuMax-TF-ADC, an antibody-drug conjugate (ADC), which is in Phase I clinical studies for the treatment of solid tumors; and Teprotumumab, a human antibody that is in Phase II clinical studies for active thyroid eye disease, as well as in Phase I clinical studies for diabetic macular edema. In addition, it has approximately 20 active pre-clinical pipeline programs, including naked antibodies, immune effector function enhanced antibodies, bispecific antibodies, and ADCs. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

173 Employees
Last Reported Date: 03/2/15
Founded in 1999

genmab a/s (GEN) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: kr11.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.2M
Compensation as of Fiscal Year 2014.

genmab a/s (GEN) Key Developments

Genmab A/S Presents at Kempen Healthcare and Life Sciences Conference - New York, Apr-16-2015

Genmab A/S Presents at Kempen Healthcare and Life Sciences Conference - New York, Apr-16-2015 . Venue: New York, New York, United States.

Genmab A/S Announces Board Appointments

At Genmab A/S' Annual General Meeting held on March 26, 2015. At the meeting Dr. Paolo Paoletti and Pernille Erenbjerg were elected to the Board of Directors for a one year period.

Genmab to Initiate Phase I MM Study Using Halozyme's Drug Delivery Platform

Halozyme Therapeutics Inc. announced that Genmab A/S has announced plans for a Phase I clinical trial of a subcutaneous formulation of the anti-CD38 antibody, daratumumab, indicated for the treatment of multiple myeloma, or MM, using the ENHANZE technology. In December 2014, Janssen Biotech Inc. (Janssen) entered into an agreement with Halozyme Therapeutics for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE technology. This agreement has the potential to lead to the development of a subcutaneous formulation of daratumumab. Daratumumab is being developed under a collaboration between Janssen and Genmab A/S since August 2012 when Genmab granted Janssen an exclusive worldwide license to develop, manufacture, and commercialize daratumumab. Daratumumab, a human monoclonal antibody that targets CD38 on the surface of multiple myeloma cells, is in clinical development as a single agent and in combination with standard of care therapies in several settings of multiple myeloma. Daratumumab may also have potential in other hematologic malignancies in which CD38 is expressed, including non-Hodgkins lymphoma and various leukemias. ENHANZE is Halozyme's proprietary drug delivery platform based on the Company's patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration. ENHANZE may also benefit subcutaneous biologics by reducing the need for multiple injections.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:DC kr514.50 DKK -3.00

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.53 EUR -0.018
arGEN-X BV €8.80 EUR -0.18
MorphoSys AG €59.80 EUR -3.01
Seattle Genetics Inc $36.13 USD -0.44
XOMA Corp $3.70 USD -0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation GEN Industry Range
Price/Earnings 87.2x
Price/Sales 30.7x
Price/Book 12.9x
Price/Cash Flow 88.5x
TEV/Sales 28.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMAB A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at